Viral illnesses - SAVIMS

Reference: Shrestha, N. K., Burke, P. C., Nowacki, A. S., Simon, J. F., Hagen, A., & Gordon, S. M. (2022). Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine. medRxiv. https://doi.org/10.1101/2022.12.17.22283625 Summary: This study evaluated the effectiveness of the bivalent COVID-19 vaccine among 51,011 employees at the Cleveland Clinic. The results indicated a 30% effectiveness

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

Restricted content

Suzanne | 16/02/2023 | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

Restricted content

Suzanne | 09/02/2023 | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Restricted content

Suzanne | 02/02/2023 | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Prevention Strategies Against COVID-19, Influenza, and RSV – SUMMARY

Director | 02/02/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2023). I-PREVENT COVID, FLU AND RSV protection. Retrieved from www.flccc.net Summary: The I-PREVENT protocol is designed for healthcare workers, high-risk individuals, and those with co-morbidities to mitigate the risks of COVID-19, influenza, and RSV infections. Recommended interventions include antiseptic mouthwashes containing chlorhexidine, povidone-iodine, or cetylpyridinium chloride, and supplementation with Vitamin D, Vitamin

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Preventative Protocols for COVID-19, Influenza, and RSV

Director | 01/02/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Reference: I-PREVENT. (2023). COVID, Flu and RSV protection. Retrieved from [source link if applicable, otherwise remove this line] Summary: The I-PREVENT protocol offers strategies for the prevention of COVID-19, influenza, and RSV. It includes pre-exposure and post-exposure prevention measures, particularly aimed at high-risk groups and healthcare workers. The pre-exposure approach recommends the use of antiseptic

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Association of Guillain-Barré Syndrome with COVID-19 Vaccination

Director | 01/02/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Abara, W. E., Gee, J., Marquez, P., Woo, J., Myers, T. R., DeSantis, A., Baumblatt, J. A. G., Woo, E. J., Thompson, D., Nair, N., Su, J. R., Shimabukuro, T. T., & Shay, D. K. (2023). Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Network Open, 6(2), e2253845. https://doi.org/10.1001/jamanetworkopen.2022.53845 Summary:

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Estimation of Number Needed to Vaccinate Against COVID-19 Hospitalisation

Director | 25/01/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: UK Health Security Agency. (2023). Estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation for primary vaccination, booster vaccination (3rd dose), autumn 2022 and spring 2023 booster for those newly in a risk group. Retrieved from [URL] Summary: The UK Health Security Agency’s report outlines the calculation of the number needed to

COVID-19, Covid-19 vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Rethinking Next-Generation Vaccines for Respiratory Viruses

Director | 11/01/2023 | COVID-19, Covid-19 vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host & Microbe, 31, 146-157. https://doi.org/10.1016/j.chom.2022.11.016 Summary: The article discusses the challenges in developing effective vaccines for respiratory viruses such as SARS-CoV-2 and influenza. These viruses often replicate rapidly in the